Biogen Inc
NASDAQ: BIIB
$139.98
-$0.21 (-0.1%)
Closing Price on March 13, 2025
BIIB Articles
A new JPMorgan research report highlights some large cap secular growth stocks that have shown strong and consistent revenue growth over the past 10 years, even during the recession.
Published:
Last Updated:
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
Published:
Last Updated:
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
Published:
Last Updated:
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
Published:
Last Updated:
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
Published:
Last Updated:
A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the S&P for the first time since early in 2011, despite displaying higher...
Published:
Last Updated:
Jefferies has four top biotech picks for 2016 that all have substantial upside and may provide investors with solid alpha for 2016.
Published:
Last Updated:
Short interest increased in most of these selected biotech stocks for the most recent settlement date.
Published:
Last Updated:
Biogen reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.
Published:
Last Updated:
Biogen is set to report its fourth-quarter financial results before the markets open Wednesday.
Published:
Last Updated:
These companies are well along in clinical trials and some are close to presenting Phase 3 results. Sticking with industry leaders always makes sense in a very volatile sector.
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.